XML 67 R46.htm IDEA: XBRL DOCUMENT v3.3.1.900
Licensing, Acquisitions and Other Arrangements (Details 2) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
May. 26, 2015
Assets acquired and liabilities assumed                        
Cash and equivalents                       $ 877
Short-term investments                       11
Accounts and other receivables                       106
Inventories                       492
Other assets                       212
Accounts payable and accrued liabilities                       (381)
Deferred income taxes                       (6,453)
Other long-term liabilities                       (254)
Total identifiable net assets                       13,160
Goodwill $ 13,168       $ 5,862       $ 13,168 $ 5,862 $ 6,277 7,610
Total assets acquired and liabilities assumed                       20,770
Fair market value step-up adjustment to inventories 445               445      
Net Revenues 6,400 $ 5,944 $ 5,475 $ 5,040 $ 5,452 $ 5,019 $ 4,926 $ 4,563 22,859 19,960 18,790  
Operating earnings (loss)                 7,537 $ 3,411 $ 5,664  
IPR&D                        
Assets acquired and liabilities assumed                        
Intangible assets                       7,180
Developed Technology Rights                        
Assets acquired and liabilities assumed                        
Intangible assets                       4,590
Licensing Agreements                        
Assets acquired and liabilities assumed                        
Intangible assets                       $ 6,780
Pharmacyclics Inc                        
Assets acquired and liabilities assumed                        
Inventories $ 356               $ 356      
Amortized period of inventory                 18 months      
Finite intangible assets weighted-average estimated useful life                 12 years      
Net Revenues                 $ 774      
Operating earnings (loss)                 (519)      
Acquisition-related compensation expense                 346      
Acquisition-related inventory step up and amortization of intangible assets                 261      
Acquisition-related transaction and integration costs                 100      
Pharmacyclics Inc | Selling General And Administrative Expenses                        
Assets acquired and liabilities assumed                        
Acquisition-related costs                 294      
Pharmacyclics Inc | Research And Development Expense                        
Assets acquired and liabilities assumed                        
Acquisition-related costs                 152      
Pharmacyclics Inc | Cost Of Sales                        
Assets acquired and liabilities assumed                        
Acquisition-related costs                 $ 261